Literature DB >> 15765200

Can changes in hydrophobicity increase the bioavailability of alpha-tocopherol?

Evelyn I Back1, Claudia Frindt, Erika Oćenásková, Donatus Nohr, Martin Stern, Hans K Biesalski.   

Abstract

BACKGROUND: Bioavailability of fat-soluble vitamins from conventional oral supplements is insufficient in some conditions in which fat digestion and absorption are chronically impaired (e. g. cystic fibrosis). AIM OF THE STUDY: We used a water-soluble form of fatsoluble vitamin E (AQUANOVA solubilisate) to create a nutritional supplement (NS) in the form of vitaminized gummi bears (with micellised water-soluble alpha-tocopheryl acetate (100 IU) and 400 mg crystalline vitamin C). We assessed the bioavailability of the NS in comparison to conventional preparations.
METHODS: The trial consisted of three study days (d0: NS sucked; d10: NS swallowed; d20: reference products swallowed). A total of 14 subjects (6 male/8 female), aged 25.3 (22.7-35.3) years, BMI 24.3 (19.0-31.7) kg/m(2) participated in the study. They had blood samples drawn after fasting for >or=12 hours and then 1, 5, 15, 30, 60, 120, 180, 240, 300 and 320 minutes after ingesting the vitamins. HPLC and a colorimetric method were used to determine vitamin E and vitamin C, respectively. Areas under the curve (AUC(0-320min)) and maximum increases in plasma concentrations (Delta concentration) were calculated to assess bioavailability.
RESULTS: The AUCs(0-320min) of alpha-tocopherol from d0 were significantly larger (p = 0.016) when compared to d20. Moreover, the maximum increase in alpha-tocopherol plasma concentrations was significantly higher for d0 (p = 0.023) and d10 (p = 0.002) when compared to d20.
CONCLUSIONS: Short-term bioavailability of AQUANOVA micellised fat-soluble vitamin E from our NS was significantly higher than from regular supplements. The NS will now be tested for its clinical efficacy in a randomized double-blind controlled intervention trial with CF patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15765200     DOI: 10.1007/s00394-005-0556-9

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  14 in total

1.  An automated assay for measuring serum ascorbic acid with use of 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy, free radical and o-phenylenediamine.

Authors:  H Ihara; N Matsumoto; Y Shino; Y Aoki; N Hashizume; S Nanba; T Urayama
Journal:  Clin Chim Acta       Date:  2000-11       Impact factor: 3.786

2.  Vitamin E deficiency neuropathy in children with fat malabsorption. Studies in cystic fibrosis and chronic cholestasis.

Authors:  R J Sokol; N Butler-Simon; J E Heubi; S T Iannaccone; H J McClung; F Accurso; K Hammond; M Heyman; F Sinatra; C Riely
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

3.  Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation.

Authors:  L Lancellotti; C D'Orazio; G Mastella; G Mazzi; U Lippi
Journal:  Eur J Pediatr       Date:  1996-04       Impact factor: 3.183

4.  Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis.

Authors:  J T Harries; D P Muller
Journal:  Arch Dis Child       Date:  1971-06       Impact factor: 3.791

5.  Effect of formulation on the bioavailability of retinol, D-alpha-tocopherol and riboflavine.

Authors:  N E Bateman; D A Uccellini
Journal:  J Pharm Pharmacol       Date:  1984-07       Impact factor: 3.765

6.  Kinetics of D-alpha-tocopherol in a water soluble base in man.

Authors:  N E Bateman; D A Uccellini
Journal:  J Pharm Pharmacol       Date:  1985-10       Impact factor: 3.765

7.  Water-miscible tocopherol is not superior to fat-soluble preparation for vitamin E absorption in cystic fibrosis.

Authors:  S Soltani-Frisk; E Gronowitz; H Andersson; B Strandvik
Journal:  Acta Paediatr       Date:  2001-10       Impact factor: 2.299

8.  Efficacy of water-soluble vitamin E in the treatment of vitamin E malabsorption in short-bowel syndrome.

Authors:  M G Traber; T D Schiano; A C Steephen; H J Kayden; M Shike
Journal:  Am J Clin Nutr       Date:  1994-06       Impact factor: 7.045

9.  Absorption of water-miscible forms of vitamin E in a patient with cholestasis and in thoracic duct-cannulated rats.

Authors:  M G Traber; H J Kayden; J B Green; M H Green
Journal:  Am J Clin Nutr       Date:  1986-12       Impact factor: 7.045

10.  Treatment of vitamin E deficiency during chronic childhood cholestasis with oral d-alpha-tocopheryl polyethylene glycol-1000 succinate.

Authors:  R J Sokol; J E Heubi; N Butler-Simon; H J McClung; J R Lilly; A Silverman
Journal:  Gastroenterology       Date:  1987-11       Impact factor: 22.682

View more
  3 in total

1.  Altered bacterial metabolism, not coenzyme Q content, is responsible for the lifespan extension in Caenorhabditis elegans fed an Escherichia coli diet lacking coenzyme Q.

Authors:  Ryoichi Saiki; Adam L Lunceford; Tarra Bixler; Peter Dang; Wendy Lee; Satoru Furukawa; Pamela L Larsen; Catherine F Clarke
Journal:  Aging Cell       Date:  2008-02-11       Impact factor: 9.304

Review 2.  Application of Nanomicelles in Enhancing Bioavailability and Biological Efficacy of Bioactive Nutrients.

Authors:  Lei Li; Yun Zeng; Minyi Chen; Gang Liu
Journal:  Polymers (Basel)       Date:  2022-08-11       Impact factor: 4.967

3.  Oral Supplementation with a Special Additive of Retinyl Palmitate and Alpha Tocopherol Reduces Growth Retardation in Young Pancreatic Duct Ligated Pigs Used as a Model for Children Suffering from Exocrine Pancreatic Insufficiency.

Authors:  Anne Mößeler; Marion Schmicke; Martin Höltershinken; Martin Beyerbach; Josef Kamphues
Journal:  Int J Mol Sci       Date:  2016-09-28       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.